CClinicalTrials.gg
Active, not recruitingNCT03865537LPS-IIUpdated Jun 21, 2024

Cold Snare Endoscopic Mucosal Resection Trial

An interventional study of Cold snare EMR and Hot snare EMR in Colonic Polyp, Colonoscopy and Complication, sponsored by White River Junction Veterans Affairs Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by White River Junction Veterans Affairs Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
990
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study compares different approaches to endoscopic mucosal resection (EMR) of large non-pedunculated colorectal polyps (≥20mm) in a 2 x 2 randomized design. The first randomization will assign half of patients to polyp resection with electrocautery ("hot" snare EMR) and half of patient to polyp resection without electrocautery ("cold" snare EMR). The second randomization will assign half of patients to polyp removal using Eleview as the submucosal injection agent, and the other half using placebo (normal saline with methylene blue) as the submucosal injection agent.

Read the detailed description

Electrocautery, or hot snare resection has long been considered the standard approach to polyp resection. A major limitation is a 5 to 10% risk of major adverse events. Recent studies suggest that snare resection without electrocautery - so-called cold snare EMR - may be safer than hot snare EMR. The concern with cold snare resection is a potentially lower efficacy, because cold snare resection requires the removal of a large polyp in smaller and greater number of pieces than with hot snare resection. This may lengthen procedure time and increase the risk of incomplete resection.

Furthermore, there is uncertainty about the optimal injection solution for lifting of the polyp prior to resection. Normal saline with methylene blue as the contrast agent is frequently used, but is limited by fast dissipation of the polyp lift. Eleview is a newly approved viscous solution (that contains methylene blue), which provides a longer polyp lift than normal saline. It is unclear how these two solutions compare with respect to resection efficacy and safety.

02

Conditions studied

  • Colonic Polyp
  • Colonoscopy
  • Complication
  • Recurrence
03

In context

Recurrence

4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.

This study's enrollment of 990 is above the median of 50 across 3,374 interventional studies indexed under Recurrence.

Browse Recurrence studies →

Lead sponsor

White River Junction Veterans Affairs Medical Center is the lead sponsor of 24 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Any patient ≥18 who presents for a colonoscopy and who does not have criteria for exclusion
  • Patients with a ≥20mm non-pedunculated colorectal polyp

Exclusion criteria

Exclusion Criteria:

  • Pedunculated polyps (as defined by Paris Classification type Ip)
  • Suspected adenocarcinoma with deep submucosal invasion
  • Patients with ulcerated depressed lesions (as defined by Paris Classification type III) or confirmed adenocarcinoma
  • Patients with inflammatory bowel disease
  • Patients who are receiving an emergency colonoscopy
  • Poor general health (ASA class>3)
  • Patients with coagulopathy with an elevated INR ≥1.5, or platelets \<50
  • Inadequate bowel preparation (Boston Bowel Prep Scale, total score ≤2)
  • Pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
990 participants (actual)

Study arms

  • Experimental
    Cold snare & Eleview injection

    Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Eleview

    Procedure: Cold snare EMR · Procedure: Eleview injection

  • Experimental
    Cold Snare & Placebo injection

    Polyp resection without electrocautery (cold snare EMR), and initial submucosal injection with Placebo

    Procedure: Cold snare EMR · Procedure: Placebo injection

  • Active comparator
    Hot snare & Eleview injection

    Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Eleview

    Procedure: Hot snare EMR · Procedure: Eleview injection

  • Active comparator
    Hot snare & Placebo injection

    Polyp resection with electrocautery (hot snare EMR), and initial submucosal injection with Placebo

    Procedure: Hot snare EMR · Procedure: Placebo injection

Interventions

  • ProcedureCold snare EMR

    Participants will have their large polyp removed without electrocautery

  • ProcedureHot snare EMR

    Participants will have their large polyp removed with electrocautery

  • ProcedureEleview injection

    Participants will have their polyp submucosally injected with Eleview

  • ProcedurePlacebo injection

    Participants will have their polyp submucosally injected with placebo

06

What researchers measure

Primary outcomes

  1. Severe Adverse Events

    Aggregate of all severe adverse events that occur at the time of the colonoscopy with resection of the large polyp or following the procedure

    Time frame: up to 30 days following the procedure

Secondary outcomes

  1. Subcategories of severe adverse events

    Bleeding, post-polypectomy syndrome, perforation, abdominal pain

    Time frame: during the procedure and up to 30 days following the procedure

  2. Performance submucosal injectate

    Injection performance

    Time frame: immediately following polyp resection during the colonoscopy

  3. Volume of submucosal injectate

    volume of injection

    Time frame: immediately following polyp resection during the colonoscopy

  4. Efficacy of submucosal injectate

    Sidney index

    Time frame: immediately following polyp resection during the colonoscopy

  5. Completeness of polyp resection

    Complete polyp removal is defined as removal of all visible polyp tissue at the end of the EMR, as assessed by the endoscopist.

    Time frame: immediately following polyp resection during the colonoscopy

  6. Intraprocedural bleeding

    bleeding that requires endoscopic intervention to stop the bleeding

    Time frame: at the time of polyp resection

  7. Polyp recurrence

    Presence of biopsy proven neoplastic polyp tissue at the EMR resection site at surveillance colonoscopy following complete polyp resection

    Time frame: at surveillance colonoscopies up to 5 years following the initial polyp resection

  8. Crossover from cold to hot snare

    Proportion of polyps in the cold snare group that could not be removed by cold snare and were removed by hot snare, categorized by size and morphology subtypes of polyps

    Time frame: at the time of polyp resection

07

Study locations

1 site
  • White River Junction VAMC
    White River Junction, Vermont 05009, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03865537
Lead sponsor
White River Junction Veterans Affairs Medical Center
Collaborators
Dartmouth College, Steris, Cosmo Pharmaceuticals
Responsible party
Dr. Heiko Pohl (Associate Professor or Medicine, White River Junction Veterans Affairs Medical Center) — Principal investigator
First posted
Mar 7, 2019
Start date
Oct 1, 2019
Primary completion
May 31, 2024
Completion
Jan 2027 (estimated)
Last update
Jun 21, 2024

Study contacts

Heiko Pohl, MD
study chair · White River Junction VAMC, Geisel School of Medicine at Dartmouth

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion